Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model
For patients with persistent pulmonary nodules in real-world cancer hospital-based cohorts, both the Brock and Sybil models had values and limitations for lung cancer risk prediction. Optimizing predictive models in this population is crucial for improving early lung cancer detection and interception.
Authors
- Carol C. Wu (ORCID: https://orcid.org/0000-0003-1005-0995)
- Haniel Alves Araújo (ORCID: https://orcid.org/0000-0002-7980-0515)
- Jia Wu (ORCID: https://orcid.org/0000-0001-8392-8338)
- Xiuning Le (ORCID: https://orcid.org/0000-0002-8554-1185)
- Don L. Gibbons (ORCID: https://orcid.org/0000-0003-2362-3094)
- Simon Heeke (ORCID: https://orcid.org/0000-0002-5916-534X)
- Bingnan Zhang (ORCID: https://orcid.org/0000-0002-1821-6243)
- Mara B. Antonoff (ORCID: https://orcid.org/0000-0001-6247-9537)
- Kang Qin (ORCID: https://orcid.org/0000-0003-2638-3655)
- Lingzhi Hong (ORCID: https://orcid.org/0000-0001-6553-3279)
- Morteza Salehjahromi (ORCID: https://orcid.org/0000-0002-7036-1683)
- Mehmet Altan (ORCID: https://orcid.org/0000-0001-9229-156X)
- Chris Plummer (ORCID: https://orcid.org/0000-0003-4135-3008)
- John Victor Heymach (ORCID: https://orcid.org/0000-0001-9068-8942)
- Edwin J. Ostrin (ORCID: https://orcid.org/0000-0002-4538-6539)
- David E. Gerber (ORCID: https://orcid.org/0000-0002-7812-6741)
- Natalie I. Vokes (ORCID: https://orcid.org/0000-0002-3766-5335)
- Jianjun Zhang (ORCID: https://orcid.org/0000-0001-7872-3477)
- J. Jack Lee (ORCID: https://orcid.org/0000-0001-5469-9214)
- Hui Li (ORCID: https://orcid.org/0000-0003-3139-2898)
- Zheng Zhang (ORCID: https://orcid.org/0000-0002-3242-5738)
- Myrna C.B. Godoy (ORCID: https://orcid.org/0000-0001-6455-6989)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Southwestern Medical Center (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-29
- DOI
- https://doi.org/10.3390/cancers17091499
- Citations
- 4
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- Novocure
- Janssen Scientific Affairs
- Innovent Biologics
- Daiichi-Sankyo
- University of Texas MD Anderson Cancer Center